A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas.
Status:
Recruiting
Trial end date:
2027-07-30
Target enrollment:
Participant gender:
Summary
This is first in human (FIH) study to a) evaluate the safety and tolerability profile of
GRC54276, b) determine the maximum tolerated dose (MTD) and recommended Phase 2 doses (RP2D),
and c) pharmacokinetic profile of GRC54276 alone and in combination with pembrolizumab or
atezolizumab in participants with advanced solid tumors and lymphomas.